Early treatment of obstructive sleep apnea may decrease the risk of Parkinson's disease, a new study published Monday finds.

If you have obstructive sleep apnea (OSA)—a condition that causes a partial or complete collapse of your upper airway while sleeping—you’re likely familiar with continuous positive airway pressure ...

A large study shows obstructive sleep apnea is linked to higher risk for Parkinson’s disease — and suggests early CPAP ...

Around 22 million Americans have sleep apnea. Traditional continuous positive airway pressure, or CPAP, machines are the standard treatment. However, they can be loud, uncomfortable and have a pesky ...

Sleep apnea is a common sleep disorder that affects more than 20 percent of people in the United States. It happens when your breathing temporarily stops while you sleep. Depending on the severity of ...

Along with diet and exercise, sleep is the third pillar of health. And frankly, a good night's sleep is often the answer to whatever ails you. But for 30 million people in the United States, sleep ...

The Food and Drug Administration today approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the ...

Sleep apnea used to be managed by puncturing the neck, but treatments for the common condition in the near-future promise to be far less intrusive. Reading time 6 minutes Snoring is routinely a ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound ...

Credit: Vivos Therapeutics. The FDA clearance was based on data from 73 patients with severe OSA. The Food and Drug Administration (FDA) has cleared the Vivos CARE (complete airway repositioning ...

In much the same way that they’re designed to expand wearers’ upper airways, Vivos Therapeutics’ slate of oral appliances have now expanded their FDA indications, too. Collectively known as the ...